SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 32.13-0.5%Nov 28 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bluegreen who wrote (16645)2/20/2004 8:19:26 PM
From: Robert K.   of 17367
 
sept,03...........................................>>>>>>
Those would include other autoimmune diseases, such as lupus, multiple sclerosis and organ transplantation. Xoma dropped studies of Raptiva for kidney transplantation, but the company, Castello said, could pick that up again, perhaps in "a year or so." Xoma and Genentech also hope to have data on a Phase II trial of Raptiva for psoriatic arthritis by the end of the year, and then determine whether to enter Phase III trials (MSNBC).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News